Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual Trigger for Oocyte Maturation in Poor Ovarian Responders
NCT04224818Phase 3
Key facts
- Status
- Completed
- Start
- Jul 2018
- Primary completion
- Aug 2019
- Countries
- 1
- Sponsor
- American University of Beirut Medical Center
- Modality
- Peptides, Small Molecules
- Drugs
- triptorelin
- Conditions
- Diminished Ovarian Reserve (DOR)
01
Overview
Phase 3, randomised trial of triptorelin in Diminished Ovarian Reserve (DOR) (2 arms), sponsored by American University of Beirut Medical Center. Primary endpoints: Number of oocytes retrieved (oocyte collection rate) and Number of mature oocytes (oocyte maturation rate). Started Jul 2018; status: completed.
02
Design
2 arms- Study design
- Randomized
Dual trigger
Triptorelin 0.3 mg + Choriomon 10,000 IU
hCG (standard)
Choriomon 10,000 IU
03
Who it enrols
Women with Poor Ovarian Reserve (Bologna criteria) defined by AMH < 1.5 ng/ml, AFC <= 7, or <= 5 oocytes in a previous cycle, with normal uterine cavity and hormonal profile.
04
Endpoints
Primary
Number of oocytes retrieved (oocyte collection rate)
Number of mature oocytes (oocyte maturation rate)
Secondary
Fertilization rate
Clinical pregnancy rate
Implantation rate
Miscarriage rate
Beyond the preview
Go deeper on NCT04224818.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224818.